Vertex Pharmaceuticals | VRTX - Trade Debtors

Stock Price
422.73
Daily Change
-7.41 -1.72%
Monthly
-4.61%
Yearly
-17.03%
Q2 Forecast
421.08

Vertex Pharmaceuticals reported $2.05B in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 777.57M 187.2M Dec/2025
Amgen USD 9.57B 1.08B Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
Biogen USD 1.87B 17M Dec/2025
BioMarin Pharmaceutical USD 908.21M 117.95M Dec/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Gilead Sciences USD 4.91B 182M Dec/2025
Incyte USD 1.05B 27.09M Mar/2026
Insmed USD 140.86M 75.6M Dec/2025
Ionis Pharmaceuticals USD 74M 8M Mar/2026
J&J USD 21.33B 3.72B Dec/2025
Merck USD 12.12B 596M Sep/2025
Moderna USD 184M 862M Dec/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 12.29B 3.3B Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Roche Holding CHF 11.9B 460M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
United Therapeutics USD 350.2M 52.5M Dec/2025
Vertex Pharmaceuticals USD 2.05B 106.4M Dec/2025